ReviewJournal of industrial microbiology & biotechnology2015
An integrated biotechnology platform for developing sustainable chemical processes.
Review in Journal of industrial microbiology & biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Recent advances in pathway engineering for the biosynthesis of 1,4-butanediol.Applied microbiology and biotechnology · 2026Review
- Production of bio-based lactones as monomers for a circular polymer economy.Nature reviews. Chemistry · 2025Review
- Streamlined identification of strain engineering targets for bioprocess improvement using metabolic pathway enrichment analysis.Scientific reports · 2023Article
- Exploring functionality of the reverse β-oxidation pathway in Corynebacterium glutamicum for production of adipic acid.Microbial cell factories · 2021Article
- In silico co-factor balance estimation using constraint-based modelling informs metabolic engineering in Escherichia coli.PLoS computational biology · 2020Article
- A Review of the Biotechnological Production of Methacrylic Acid.Frontiers in bioengineering and biotechnology · 2020Review
- Awakening sleeping beauty: production of propionic acid in Escherichia coli through the sbm operon requires the activity of a methylmalonyl-CoA epimerase.Microbial cell factories · 2017Article
- Gas fermentation: cellular engineering possibilities and scale up.Microbial cell factories · 2017Review
- Production of C2-C4 diols from renewable bioresources: new metabolic pathways and metabolic engineering strategies.Biotechnology for biofuels · 2017Review
- Engineered biosynthesis of biodegradable polymers.Journal of industrial microbiology & biotechnology · 2016Review
- LCA of 1,4-Butanediol Produced via Direct Fermentation of Sugars from Wheat Straw Feedstock within a Territorial Biorefinery.Materials (Basel, Switzerland) · 2016Article
- Systems Metabolic Engineering of Escherichia coli.EcoSal Plus · 2016Review
- Editorial.Journal of industrial microbiology & biotechnology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genomatica has established an integrated computational/experimental metabolic engineering platform to design, create, and optimize novel high performance organisms and bioprocesses. Here we present our platform and its use to develop E. coli strains for production of the industrial chemical 1,4-butanediol (BDO) from sugars. A series of examples are given to demonstrate how a rational approach to strain engineering, including carefully designed diagnostic experiments, provided critical insights about pathway bottlenecks, byproducts, expression balancing, and commercial robustness, leading to a superior BDO production strain and process.
Indexed as
Identifiers
25416472What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.